News

July 6, 2022

Blue Fin Group Presents Market Research Study on Current and Future Payer Management in Oncology

Blue Fin Group today announced a new market research study video assessing current and future payer management in oncology including influences on payer decision-making to prefer drugs in oncology, top barriers and influencers to manage oncolytics, and oncology management expectations in the next three years, including increasing contracting for preference and value-based contracting.




April 20, 2022

Registration Opens for Access Insights Conference 2022

IntegriChain opens registration to all pharma manufacturers for the Access Insights Conference 2022, now co-hosted by Blue Fin Group, an IntegriChain Company. The Access Insights Conference will be held October 17-19, 2022, at the Marriott Baltimore Harborside. Designed for commercial, operational, and financial teams at pharma manufacturers, the conference will feature industry executive and practitioner panels, exclusive ICyte Benchmarks presentations, and strategic and tactical programs focused on driving patient access and therapy commercialization.




January 20, 2022

IntegriChain Announces Leadership Changes

IntegriChain announced key promotions on its executive leadership team following its recent rapid growth: Josh Halpern is now President and Chief Operating Officer (COO); Brad Burget is now Chief Technology Officer (CTO); Vickie Koshushchenko is now Chief People Officer; and William Roth is General Manager and Managing Partner of Blue Fin Group, an IntegriChain Company.


January 20, 2022

IntegriChain Acquires Blue Fin Group, Combining Therapy Commercialization Expertise with Leading Technology, Data, and Business Operations

IntegriChain has acquired Blue Fin Group, a full-service professional management consulting firm delivering research, strategy, and implementation services to help manufacturers optimize access. Blue Fin Group’s team of nearly 45 consultants and professionals with expertise in market access, drug commercialization, channel strategy, patient funnel pull through, and GTN optimization will operate as an independent division of IntegriChain.


December 15, 2021

IntegriChain Secures Leadership in State Price Transparency Reporting

IntegriChainhas secured leadership in State Price Transparency Reporting for Life Sciences manufacturers. Nearly 80 Life Sciences manufacturer customers rely on IntegriChain’s team of 12 subject matter experts on staff to advise and implement reporting programs. In addition, IntegriChain has generated more than 500 reports to state agencies on behalf of its Life Sciences manufacturer customers to meet the transparency requirements.


adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper